Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis by Gambella, M. et al.
1 
 
 
 
 
 
This is an author version of the following publication:  
Questa è la versione dell’autore della seguente pubblicazione:  
 
Gambella, M., Omedé, P., Spada, S., Muccio, V. E., Gilestro, M., Saraci, E., … Oliva, S. (2019). 
Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative 
polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled 
analysis. Cancer, 125(5), 750–760. https://doi.org/10.1002/cncr.31854 
 
 
 
The definitive version is available at:  
La versione definitiva è disponibile alla URL:  
 
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31854 
 
 
2 
 
Minimal Residual Disease by Flow Cytometry and ASO-RQ-PCR in 
Myeloma Patients Receiving Lenalidomide Maintenance: A 
Pooled Analysis 
 
MRD and ASO-RQ-PCR in MM patients 
 
Manuela Gambella1, Paola Omedé1, Stefano Spada1, Vittorio Emanuele Muccio1, Milena 
Gilestro1, Elona Saraci1, Sara Grammatico2, Alessandra Larocca1, Concetta Conticello3, Annalisa 
Bernardini1, Barbara Gamberi4, Rossella Troia1, Anna Marina Liberati5, Massimo Offidani6, 
Alberto Rocci7,8, Antonio Palumbo1*, Michele Cavo9, Pieter Sonneveld10, Mario Boccadoro1, and 
Stefania Oliva1 
 
1Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città 
della Salute e della Scienza di Torino, Torino, Italy; 2Haematology, Department of Cellular 
Biotechnologies and Hematology, Policlinico Umberto 1, “Sapienza” University, Rome, Italy; 3Division of 
Hematology, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy; 
4Ematologia, AUSL-IRCSS, Reggio Emilia, Italy; 5Università Degli Studi di Perugia, Perugia, Italy; 6Clinica 
di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy; 7Haematology Department, Manchester 
University NHS Foundation Trust, Manchester Royal Infirmary, Manchester, United Kingdom; 8Faculty 
of Biology, Medicine and Health, School of Medical Science, Division of Cancer Sciences, University of 
Manchester, Manchester, United Kingdom; 9"Seràgnoli" Institute of Hematology, Bologna University 
School of Medicine, Bologna, Italy; 10Department of Hematology, Cancer Institute Erasmus Medical 
Center, Rotterdam, the Netherlands. *Currently a Takeda employee. 
 
Correspondence: Dr. Stefania Oliva, M.D., Ph.D. Myeloma Unit, Division of Hematology, University of Torino, 
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126, Torino, Italy. 
Tel +39 0116334301; fax +39 0116334187. E-mail: stefania.olivamolinet@gmail.com 
 
 
 
 
  
3 
 
 
 
Abstract 
Background. Minimal residual disease (MRD) is one of the most relevant prognostic factors in 
multiple myeloma (MM) patients; nevertheless, the impact of maintenance therapy on MRD 
levels is still unclear. We evaluated the role of MRD by multiparameter flow cytometry (MFC) 
and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-
PCR) as predictor of progression-free survival (PFS) in newly diagnosed MM (NDMM) patients 
receiving lenalidomide maintenance until progression. 
Methods. Seventy-three NDMM patients enrolled in the RV-MM-EMN-441 and in the RV-MM-
COOP-0556 phase-III trials achieving ≥very good partial response after 
intensification/consolidation were included. Median age was 57 years (IQR:53-61) and all 
patients received Lenalidomide maintenance until progression. MRD was evaluated on bone 
marrow after intensification/consolidation, after 6 courses of maintenance and then every 6 
months until clinical relapse, using both ASO-RQ-PCR (sensitivity of 10−5) and MFC (sens. 10-4-
10-5).  
Results. After intensification/consolidation, 33/72 (46%) patients achieved molecular-
complete response (m-CR) and 44/70 (63%) patients flow-complete response (flow-CR). 
Almost 27% of MRD-positive patients after consolidation became MRD-negative during 
maintenance. After a median follow-up of 38 months, PFS was prolonged in patients achieving 
MRD negativity during maintenance, both by ASO-RQ-PCR (HR:0.29, 95%CI 0.14-
0.62,p=0.0013) and MFC (HR:0.19, 95%CI 0.09-0.41,p<0.001). The impact of MRD negativity 
on PFS was similar in all subgroups (ASCT/no-ASCT, ISSI/II/III, High-/Standard-risk 
cytogenetics), and the two techniques were highly correlated.  
Conclusions. MRD is a stronger predictor of PFS than standard risk factors and Lenalidomide 
maintenance further increases MRD negativity rate. 
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Introduction 
Multiple myeloma (MM) is a plasma cell malignancy, and its outcome has markedly improved 
during the last 10-15 years thanks to the introduction of novel agents and autologous stem cell 
transplantation (ASCT). Recently, consolidation and maintenance therapy increased rates and 
depth of response.1,2 Because most of patients with complete response (CR) ultimately relapse, 
more sensitive methods are needed to detect and quantify minimal residual disease (MRD). 
Several techniques have been explored, such as quantitative allelic-specific oligonucleotide 
real-time quantitative polymerase chain reaction (ASO-RQ-PCR) and high-throughput next-
generation sequencing (NGS) for molecular response evaluation; multiparameter flow 
cytometry (MFC) and next-generation flow (NGF) to evaluate bone marrow (BM) plasma cell 
residual disease. The lower is the MRD level with the higher sensitivity technique, the longer 
the progression-free survival (PFS).3 A recent meta-analysis showed an advantage for MRD-
negative over MRD-positive patients. In particular, in patients achieving conventional CR, MRD 
results were reported in five studies for PFS4–8 and in six studies for OS.4–10 MRD-negative 
patients had a significantly better PFS (HR 0.44, P<0.0001) and OS (HR 0.47, P<0.0001) 
compared with MRD-positive patients. Moreover, five studies evaluated MRD before and after 
ASCT, and found that patients achieving MRD negativity increased after ASCT.11–15 Similarly, 
two studies found that maintenance therapy increased the proportion of patients achieving and 
maintaining MRD-negative status.11,12 This meta-analysis also showed that patients with 
favorable cytogenetic profile who achieved MRD-negative status had the best OS; conversely, 
patients with high-risk cytogenetic profile who remained MRD-positive had the worst outcome. 
We evaluated MRD by ASO-RQ-PCR and MFC in patients who received Bortezomib or 
Lenalidomide-based front-line induction followed by ASCT/ no-ASCT consolidation and who 
started Lenalidomide maintenance. A pooled analysis was performed, due to the suitable 
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number of patients enrolled whose MRDs had been recorded at different time points during 
lenalidomide maintenance. 
 
Methods 
Patients and study design 
We pooled 105 newly diagnosed MM (NDMM) patients enrolled in two phase III clinical trials: 
the RV-MM-EMN-441 (ClinicalTrials.gov identifier: NCT01091831)16 and the RV-MM-COOP-
0556 (ClinicalTrials.gov identifier: NCT01208766).17 The two study designs are illustrated in 
the supplementary appendix (Figure S1). In the RV-MM-EMN-441 study, patients were 
randomized at enrollment in a 1:1:1:1 ratio to receive consolidation with six cycles of 
Cyclophosphamide-Lenalidomide-Dexamethasone (CRD) or Melphalan-conditioned 
Autologous Stem-Cell Transplantation (ASCT), and maintenance with either Lenalidomide or 
Lenalidomide-prednisone until relapse or intolerance. Patients received four cycles of 
Lenalidomide-Dexamethasone (RD) induction, followed by mobilization and stem cell 
collection. Subsequently, when eligibility for consolidation was confirmed, the treatment 
allocation was disclosed. In the RV-MM-COOP-0556, patients received 3-4 cycles of 
Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction, followed by mobilization 
and stem cell collection. Afterwards, patients were randomized to receive 4 cycles of 
Bortezomib-Melphalan-Prednisone (VMP) or 1-2 cycles of High-Dose-Melphalan (HDM) 
followed by ASCT. After intensification, patients were secondly randomized to receive 2 cycles 
of Bortezomib-Lenalidomide-Dexamethasone (VRD) consolidation or no consolidation, 
followed by Lenalidomide maintenance in both arms until progression or intolerance. 
Response to treatment was assessed according to the IMWG criteria.18 Patients who achieved 
at least a VGPR after intensification/consolidation and had plasma cell infiltration ≥5% at 
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baseline were eligible for the MRD sub-study. This cut-off was chosen because of the technical 
issues in obtaining the molecular marker in patients with a lower plasma cell infiltration at 
baseline. MRD analysis was performed on BM aspirates collected at different time-points: after 
intensification/consolidation, after 6 courses of maintenance, and then every 6 months until 
clinical relapse. The MRD sub-study was conducted in accordance with the Declaration of 
Helsinki principles and was approved by the relevant Institutional Review Boards. Written 
informed consent was obtained from all patients. 
 
MRD assessment by MFC 
MFC assays were performed on BM aspirates centralized to a single laboratory (Laboratory of 
Cytofluorimetry-University of Turin, Italy). BM processing was done within 24-48 hours from 
collection according to the EuroFlow guidelines.19,20 In the RV-MM-EMN-441 trial, MRD was 
investigated using either two tubes with six-colors (tube 1: CD138FITC/CD56PE/CD20PerCp-
Cy5.5/CD117APC/CD45APC-H7/CD38PE-Cy7; tube 2: 
cyKappaFITC/cyLambdaPE/CD19PerCp-Cy5.5/CD56APC/CD45APC-H7/CD38PE-Cy7). 
Acquisition and analyses were performed using a FACSCanto II Flow Cytometer equipped with 
FACSDiva software (BD Biosciences, San Josè, CA) and a minimum of 1 x 106 of events for each 
sample were acquired. In the RV-MM-COOP-0556 trial, we switched to a panel of two tubes with 
eight-color (tube 1: CD81F/CD27PE/CD138PC5.5/CD19PE-Cy7/CD20APC/CD38PB/CD45KO; 
tube 2: cyKappaFITC/cyLambdaPE/CD138PC5.5/CD19PE-Cy7/CD56APC/CD117APC-
A750/CD38PB/CD45KO); acquisition and analyses were performed using a NAvios flow 
cytometer equipped with Kaluza software (Beckman Coulter, Brea, CA) and a minimum of 2 x 
106 of events for each sample were acquired. Flow-CR was defined as the detection of <20 clonal 
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plasma cells among ≥200.000 nucleated cells at a sensitivity level of 10-4 to 10-5 in two 
consecutive evaluations. 
 
MRD assessment by ASO-RQ-PCR 
Genomic DNA from BM samples was isolated using DNAzol reagent (Life Technologies-
Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions. Patient-specific IgH 
rearrangements were amplified and directly sequenced from genomic DNA at diagnosis,21 
sequences were analyzed by IMGT/V-QUEST tool [http://www.imgt.org]22,23 and patient-
specific ASO-primers and consensus probes were designed as previously described.21 IgH-
based MRD detection by ASO-RQ-PCR was performed using an AbiPrism7900HT (Life 
Technologies-Applied Biosystems, Carlsbad, CA, USA) and MRD analysis was interpreted 
following the Euro-MRD guidelines.24 Molecular-CR (m-CR) was defined as two consecutive 
negative MRD results by ASO-RQ-PCR with minimal sensitivity of 10−5. The molecular MRD 
kinetics analysis was performed using the observed marginal means of natural logarithms (ln) 
PCR values.  
 
Cytogenetic characterization 
Fluorescent in situ hybridization (FISH) was performed on purified CD138+ cells obtained from 
BM at diagnosis following standard procedure. Patients were divided in two groups according 
to their FISH profile: high-risk, with at least one of del17p13 or t(4;14) or t(14;16); or standard-
risk, without any of the previous chromosomal abnormalities. When such data were not 
available, patients were included in the missing data category. 
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Statistical analysis 
Data of the two trials were pooled together and analyzed. MRD population was defined as 
patients with an available MRD sample before and/or after starting maintenance. PFS was 
calculated from date of BM sampling before maintenance to the date of progression or death or 
the date the patient was last known to be in remission. OS was calculated from date of BM 
sampling before maintenance to the date of death or the date the patient was last known to be 
alive. Time-to-event data were analyzed using the Kaplan–Meier method, log-rank test was 
used to compare curves. Multivariate Cox proportional hazards models were used to estimate 
hazard ratios (HRs) and the 95% confidence intervals (CIs) for MRD status, gender, age, 
International Staging System (ISS), cytogenetic risk and intensification/consolidation therapy 
(ASCT and no ASCT). Subgroup analyses were performed to determine the consistency of 
effects of MRD-negative vs MRD-positive in the different subgroups, using interaction terms 
between MRD status and each of the covariate included in the Cox model. All HRs were 
estimated with their 95% confidence intervals (95%CI) and two-sided p-values. Pearson 
correlation coefficient (r) was used to compare methods for MRD analysis (ASO-RQ-PCR and 
MFC). Data were analyzed as of December, 2017 using R (Version 3.1.1). 
 
 
Results 
Patient characteristics and MRD after intensification/consolidation 
Overall, 105 patients who achieved ≥VGPR and who had BM plasma cell infiltration ≥5% at 
baseline were enrolled in the MRD sub-study. A total of 73 (70%) could be analyzed, 32 (30%) 
could not due to unsuccessful sequencing or lack of clonality (Figure S2). Median age was 57 
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years (IQR 53 to 61 years); 10 patients (14%) had ISS stage III and 24 (33%) had high-risk 
cytogenetic profile (Table 1). Thirty-five patients received ASCT intensification/consolidation 
(40% achieved a VGPR and 60% a CR or sCR), whereas 38 patients did not (39% achieved a 
VGPR and 61% a CR or sCR).  
Before maintenance, 33/72 (46%) patients achieved m-CR (in 1 patient, sample was not 
collected at pre-maintenance) and 44/70 (63%) patients achieved flow-CR (in 1 patient, sample 
was not collected at pre-maintenance; in 2 patients, samples could not be evaluated due to low 
cellularity or hemodilution), with a higher proportion in the ASCT setting (Figure S3).  
All 73 patients started maintenance with Lenalidomide. The achievement of MRD negativity 
after intensification/consolidation significantly improved PFS both by ASO-RQ-PCR (median 
not reached vs 37.1 months for MRD negative vs positive, respectively, p=0.01) and MFC 
(median not reached vs 26 months, for MRD-negative vs MRD-positive, respectively, p=0.002).         
 
MRD status during maintenance 
At the time of data cut-off, the median duration of maintenance was 29.1 months (IQR 16.4-
40.4), 9 patients discontinued therapy due to adverse events, including a second cancer (Figure 
S2). Lenalidomide-maintenance therapy further improved the rates of MRD negativity: among 
MRD-positive patients after intensification/consolidation, 12/39 (31%) obtained a m-CR and 
6/26 (23%) obtained a flow-CR during maintenance: the higher negativity rate in the first 
group could partially explain the better PFS obtained in patients MRD positive by ASO-RQ-PCR 
after intensification/consolidation compared with those MRD positive by MFC.  
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In particular, 9 m-CR (4 after ASCT and 5 after CRD or VMP) and 5 flow-CR (2 after ASCT and 3 
after CRD or VMP) were obtained after 6 months of starting maintenance, 1 flow-CR after 18 
months, 2 m-CR after 18 months and 1 m-CR after 24 months. Both ASO-RQ-PCR and MCF 
showed that the achievement of MRD negativity during maintenance significantly improved 
PFS in all patients, with median PFS not reached with both techniques as compared with 26 
months for persistent MRD-positive patients by ASO-RQ-PCR (p<0.001) and 19.5 months for 
persistent MRD-positive patients by MFC (p<0.001) (Figure 1). When compared with baseline 
prognostic factors for MM in a Cox model for PFS, MRD negativity was the most significant 
factor to reduce the risk of progression or death by using both methods (HR 0.29, 95%CI 0.14-
0.62, p=0.001 by ASO-RQ-PCR; and HR 0.19, 95%CI 0.09-0.41, p<0.001 by MFC) (Figure 2).  
By subgroup analyses, in MRD-negative patients, PFS was similar between ASCT vs no ASCT, as 
well as between patients with ISS I vs II/III (Figure 3). Importantly, MRD-negative patients with 
high-risk cytogenetic profile had a longer PFS (median not reached by both ASO-RQ-PCR and 
MFC) versus MRD-positive patients (median: 22.6 months by ASO-RQ-PCR and 15.4 by MFC) 
(Figure 4). Both MRD methods showed significantly prolonged OS for all MRD-negative 
patients, with 4-year OS of 84% and 80%, compared with 60% and 61% in ASO-RQ-PCR and 
MFC MRD-positive patients (p=0.02 and P=0.06, respectively) (Figure 5).  
Moreover, patients with persistent MRD negativity during maintenance had the best outcome 
compared with patients who became MRD-positive during maintenance or were MRD-positive 
during the whole treatment (Figure S4). In fact, as previously reported,25 we identified three 
groups of patients with different molecular MRD kinetic patterns: i) 37 patients showed a 
persistent MRD response (51%) achieving a long-lasting m-CR until 36 months of maintenance, 
with a median tumor burden reduction of 10 ln-PCR, and in this group only 7 (19%) patients 
relapsed; ii); 14 patients experienced a transient MRD response (19%) achieving an initial MRD 
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response with a median tumor burden reduction of 8 ln-PCR; nevertheless, MRD subsequently 
reappeared, with a median increase of 4 ln-PCR, and in this group 9 patients relapsed (64%); 
iii) 22 patients showed a minimal MRD response (30%) with a median tumor burden reduction 
of 5 ln-PCR, and in this group 15 (68%) patients progressed. The same trend was observed in 
the MFC analysis (Figure S5). Finally, MRD relapse anticipated myeloma progression by a 
median of 8-9 months; 3 patients experienced extramedullary relapse and only 1/3 was 
previously MRD-positive.26  
 
Comparison of MFC and ASO-RQ-PCR analyses  
Overall, MFC and ASO-RQ-PCR methods had a highly significant level of concordance for MRD 
analysis (r=0.9, p<0.001) (Figure 6). A total of 317 samples were analyzed for MRD detection 
both by MFC and by ASO-RQ-PCR. The two methods were concordant in 285 (90%) analyses, 
both MRD-positive in 34% or both MRD-negative in 56% analyses. Discordances between the 
two methods were found in 32 (10%) paired samples, in particular 27/203 (13%) MFC-
negative samples were PCR-positive, while 5/114 (4%) MFC-positive samples were PCR-
negative.  
 
Discussion 
Depth of response is one of the most relevant clinical prognostic factors in MM. Thanks to 
effective drug-combinations and the positive results obtained with immunotherapy, deeper 
responses (CR) can now be achieved. Therefore, physicians are re-defining the goal of therapy, 
focusing on long-term control, quality of life and even cure.27 MRD analysis is a valid tool to 
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better characterize response. Here, we assessed MRD both by ASO-RQ-PCR and MFC assays in 
NDMM patients eligible for high-dose therapy who received intensification/consolidation with 
Bortezomib and Lenalidomide-based strategies after front-line induction, followed by 
Lenalidomide maintenance. In a previous report26 on a small cohort of the RV-MM-EMN-441 
study, we found a significant impact of MRD on PFS. Yet, a correlation between the molecular 
and immunophenotypic techniques was not possible due to the small number of patients with 
detectable molecular marker. In this pooled analysis, we evaluated both techniques in a larger 
series and both methods confirmed the significant impact of MRD on PFS (HR 0.29, p=0.001 
and HR 0.19, p<0.001, respectively). Of note, sensitivity was slightly higher for ASO-RQ-PCR 
(10-5) but, moving from a 6–colour to a 2nd generation flow technique in the majority of our 
samples series (73%), we observed an improvement in the level of MRD sensitivity by MFC (10-
4 to 10-5).  
In line with other studies,28,29 we observed a high correlation between the two MRD techniques 
(r=0.9, p<0.001) and discordances only in 10% of paired samples. In addition, ASO-RQ-PCR was 
applicable only in 70% of samples (excluding samples with less than <5% BM plasma cells), 
owning to the lack of clonality and unsuccessful sequencing; whereas MFC showed 97% of 
feasibility (9 samples out of a total of 327 were not evaluable due to low quality or 
hemodilution). Discordant results could be due to the half-life of M-components that disappear 
over a prolonged time compared with rapid induction of apoptosis of BM PCs.5 Moreover, 
discordances could be attributed to different sensitivity and the different analyzed target. The 
newer techniques (NGS/NGF) can overcome these limits and are now accepted as standardized 
MRD assessment procedures. Moreover, the use of functional whole body imaging techniques 
such as PET/CT has highlighted the problem of spatial heterogeneity,30 with negativity on BM 
analysis but with presence of skeletal lesion or extramedullary disease. In fact, we missed 2/3 
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extramedullary relapses by evaluating the BM compartment only. Therefore, these techniques 
may be considered complementary with sensitive immunophenotypic and molecular-based 
assays. Attempts to standardize results interpretation are ongoing.31 Novel emerging 
technologies are evaluating the possibility to explore MRD in peripheral blood circulating 
tumor cells (CTCs) or by ultra-deep sequencing of cell-free DNA. Nevertheless, these methods 
can help to explore mutational profile and subclonal composition of MM cells rather than 
detecting MRD, due to the potential lack of sensitivity in peripheral blood after treatment.32–34  
We confirmed that MRD negativity is a strong prognostic factor in MM patients, together with 
baseline clinical and biological characteristics (ISS, cytogenetic risk, therapy). Importantly, 
MRD-negative patients with high-risk cytogenetics had prolonged PFS (median not reached by 
both ASO-RQ-PCR and MFC) versus MRD-positive patients (median 22.6 months by ASO-RQ-
PCR and 15.4 by MFC). This observation is in line with data from a Spanish study, where the 
presence of baseline high-risk cytogenetic features and persistent MRD at day 100 post-
transplant were associated with early relapse.6 This is a very high-risk patient population and 
early intervention is mandatory, whereas the achievement of molecular- or flow-CR can 
overcome the poor outcome with high-risk cytogenetics.  
One of the limitations of this pooled analysis was identified in the relatively small sample size, 
which limits the multivariate and subgroup analyses. In fact, in our Cox model, the impact of 
cytogenetics – as well as other well-known prognostic factors for MM – is not as significant as 
expected. Moreover, another aspect that affected the number of patients in the subgroup 
analysis is that many high-risk patients may not have reached the first MRD assessment point. 
Finally, another limitation is that we could not analyze the overall population of the two studies 
at the completion of consolidation because we did not assess all ≥VGPR patients by both 
techniques and, as a consequence, it was impossible to perform an intention-to-treat analysis 
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considering the missing patients as positive (there would be the chance to mistakenly include 
a lot of CR or VGPR patients). MRD may help define the success of a treatment and is a valid tool 
to compare different strategies, particularly in randomized trials. Here, we demonstrated that 
higher MRD negativity rates are achieved in the transplant arms (56-67% by ASO-RQ-PCR and 
MFC, respectively) vs no transplant (37%-59% by ASO-RQ-PCR and MFC, respectively); both 
source studies demonstrated a superior outcome with high-dose therapy vs CRD or VMP 
intensification.16,17 Consistently, in the IFM/DFCI study, more patients achieved MRD negativity 
in the transplant arm, with no PFS difference in patients achieving MRD negativity according to 
treatment arm.35,36 Similar results were reported in the MRC study comparing conventional 
chemotherapy to immunomodulatory drugs prior to transplant: although more patients 
achieved MRD negativity with immunomodulatory-based induction, no survival differences 
were seen according to type of induction.37 Therefore, choosing a regimen that increases the 
chance of MRD negativity is crucial. Castor and Pollux studies, investigating the addition of 
Daratumumab to RD or VD in relapsed/refractory MM patients, also confirmed the better 
outcome of MRD-negative patients, regardless of previous therapies (Daratumumab-VD or RD 
vs VD or RD alone), although the experimental arms led to higher rates of MRD negativity.38–40  
We demonstrated that Lenalidomide continuous treatment can further improve quality of 
response or maintain it over time, suggesting that both MRD negativity and continuous therapy 
may be important in long-term outcome. In our analysis, almost one third of MRD-positive 
patients became MRD-negative during maintenance treatment and this substantially confirmed 
the similar trend of thalidomide maintenance in the analysis by Rawstron et al.41 Of note, only 
a prospective study analyzing maintenance versus no maintenance could really confirm these 
data, since a delayed response to consolidation/intensification could blind the authentic 
maintenance response, especially because most were obtained in the first 6 months. Finally, on 
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the basis of these data, we could speculate that the earlier one achieves MRD negativity the 
better is the outcome, especially if it is persistent during the whole treatment.  
Future randomized clinical trials based on MRD status at different time points will confirm such 
important results and will establish the role of delayed transplantation, consolidation vs no 
consolidation, and length of maintenance after front-line therapy.  
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Table 1. Patient characteristics  
                                       N=73 
Age (years)  
Median (IQR) 57 (53 - 61) 
Gender N (%)  
M 37 (51) 
ISS  
I 30 (41) 
II 33 (45) 
III 10 (14) 
Creatinine (mg/dL)  
Median (IQR) 0.9 (0.75 - 1.01) 
LDH (U/L)  
Median (IQR) 302 (209 - 360) 
Missing data N (%) 8 (11) 
Cytogenetic features N (%)  
Deletion 17p 7 (10) 
Translocation (4;14) 17 (23) 
Translocation (14;16) 2 (3) 
High risk 24 (33) 
Missing data 6 (8) 
Trial  
RV-MM-EMN-441 25 (34) 
RV-MM-COOP-0556 48 (66) 
Random N (%)  
no ASCT 38 (52) 
ASCT 35 (48) 
IQR: interquartile range, ISS: International Staging System, LDH: lactate dehydrogenase, FISH: fluorescence in situ 
hibridization, ASCT: autologous stem cell transplantation 
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Figures 
 
Figure 1. Kaplan-Meier estimates of PFS during maintenance 
PFS analysis by A) ASO-RQ-PCR; B) MFC. 
 
 
 
Legend. PFS, progression-free survival; ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative 
polymerase chain reaction; MFC, multiparameter flow cytometry; m-CR, molecular-complete response; flow-CR, 
flow-complete response. 
 
Figure 2. Cox model for PFS during maintenance 
Cox analysis by A) ASO-RQ-PCR; B) MFC.  
 
 
 
Legend. PFS, progression-free survival; ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative 
polymerase chain reaction; MFC, multiparameter flow cytometry; m-CR, molecular-complete response; flow-CR, 
flow-complete response; MRD, minimal residual disease; PD, progressive disease; HR, hazard ratio; CI, confidence 
interval. 
 
Figure 3. Kaplan-Meier estimates of PFS during maintenance according to therapy and 
ISS   
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PFS analysis among A) ASCT vs no ASCT MM patients by ASO-RQ-PCR; B) ASCT vs no ASCT MM 
patients by MFC; C) ISS I vs ISS II/III MM patients by ASO-RQ-PCR and D) ISS I vs ISS II/III MM 
patients by MFC. 
 
 
 
Legend. PFS, progression-free survival; ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative 
polymerase chain reaction; MFC, multiparameter flow cytometry; m-CR, molecular-complete response; flow-CR, 
flow-complete response; ISS, International Staging System; MM, multiple myeloma; ASCT, autologous stem-cell 
transplantation. 
 
Figure 4. Kaplan-Meier estimates of PFS during maintenance according to cytogenetic 
risk 
PFS analysis among patients with standard risk cytogenetic A) MRD negative vs MRD positive 
by ASO-RQ-PCR; B) MRD negative vs MRD positive by MFC; PFS analysis among patients with 
high risk cytogenetic; C) MRD negative vs MRD positive by ASO-RQ-PCR; D) MRD negative vs 
MRD positive by MFC. 
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Legend. PFS, progression-free survival; ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative 
polymerase chain reaction; MFC, multiparameter flow cytometry; m-CR, molecular-complete response; flow-CR, 
flow-complete response; MRD, minimal residual disease; ISS, International Staging System. 
 
Figure 5. Kaplan-Meier estimates of OS during maintenance 
OS analysis by A) ASO-RQ-PCR; B) MFC. 
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Legend. OS, overall survival; ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative polymerase chain 
reaction; MFC, multiparameter flow cytometry; m-CR, molecular-complete response; flow-CR, flow-complete 
response. 
 
Figure 6. Correlation between MRD results by ASO-RQ-PCR and by MFC  
 
 
 
Legend. ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative polymerase chain reaction; MFC, 
multiparameter flow cytometry; MRD, minimal residual disease.
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SUPPLEMENTARY APPENDIX 
 
 
 
 
 
 
 
 
 
Figure S1. Study designs: (A) RV-MM-EMN-441; (B) RV-MM-COOP-0556 
 
 
Figure S2. Flow diagram 
 
 
Figure S3. MRD status after intensification/consolidation. MRD status by (A) ASO-RQ-PCR; 
(B) MFC 
 
 
Figure S4. Kaplan-Meier estimates of PFS and OS during maintenance  
PFS analysis among patients with persistent MRD negativity and patients who became MRD 
positive by (A) ASO-RQ-PCR, (B) MFC; OS analysis among patients with persistent MRD 
negativity and patients who became MRD positive by (C) ASO-RQ-PCR, (D) MFC. 
 
 
Figure S5. MRD kinetics: (A) ASO-RQ-PCR; (B) MFC 
Blue line, patients with a stable MRD response; green line, patients with a transient MRD 
response; red line, patients with a minimal MRD response. 
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Figure S1. Study designs: (A) RV-MM-EMN-441; (B) RV-MM-COOP-0556 
 
 
 
 
RD, Lenalidomide-Dexamethasone; CTX, Cyclophosphamide; PBPC, peripheral blood progenitor cells; CRD, 
Cyclophosphamide-Lenalidomide-Dexamethasone; MEL200, Melphalan 200/mg2; ASCT autologous stem-cell 
transplantation; R, Lenalidomide; RP, Lenalidomide-Prednisone; VCD, Bortezomib-Cyclophosphamide-
Dexamethasone; VMP, Bortezomib-Melphalan-Prednisone; VRD, Bortezomib-Lenalidomide-Dexamethasone. 
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Figure S2. Flow diagram 
 
 
 
 
VGPR, very good partial response; ASCT, autologous stem-cell transplantation; CR, complete response; sCR, 
stringent complete response. 
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Figure S3. MRD status after intensification/consolidation. MRD status by (A) ASO-RQ-
PCR; B) MFC 
 
 
 
 
 
MRD, minimal residual disease; MFC, multiparameter flow cytometry; ASO-RQ-PCR, allelic-specific oligonucleotide 
real-time quantitative polymerase chain reaction; ASCT, autologous stem-cell transplantation; mCR, molecular-
complete response; flow-CR, flow-complete response. 
31 
 
Figure S4. Kaplan-Meier estimates of PFS and OS during maintenance 
PFS analysis among patients with persistent MRD negativity and patients who turned to MRD 
positive by (A) ASO-RQ-PCR, (B) MFC; OS analysis among patients with persistent MRD 
negativity and patients who turned to MRD positive by (C) ASO-RQ-PCR, (D) MFC. 
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MRD, minimal residual disease; PFS, progression-free survival; OS, overall survival; MFC, multiparameter flow 
cytometry; ASO-RQ-PCR, allelic-specific oligonucleotide real-time quantitative polymerase chain reaction; ASCT, 
autologous stem-cell transplantation; mCR, molecular-complete response; flow-CR, flow-complete response. 
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Figure S5. MRD kinetics: (A) ASO-RQ-PCR; (B) MFC 
Blue line, patients with a stable MRD response; green line, patients with a transient MRD 
response; red line, patients with a minimal MRD response. 
 
 
 
MRD, minimal residual disease; MFC, multiparameter flow cytometry; ASO-RQ-PCR, allelic-specific oligonucleotide 
real-time quantitative polymerase chain reaction. 
 
 
